DNA-Methylation for Risk-Stratification of Women Without a Fully Visible Transformation Zone at Colposcopy: A Cross-Sectional Study.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 40654017.
- Also identified by DOI 10.1111/1471-0528.18288.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To evaluate the performance of DNA methylation markers for the detection of cervical precancer among screening-positive older women without a fully visible transformation zone at colposcopy (TZ3). Cross-sectional study. Colposcopy clinics, Central Denmark Region, 2019-2021. Women ≥ 45 years with a TZ3 at colposcopy. Participants referred for colposcopy due to an abnormal cervical screening test underwent cervical cytology sampling, biopsies and a large loop excision of the transformation zone (LLETZ). Cytology samples were analysed for DNA methylation markers: FAM19A4/miR124-2, ARID3C/ARL5C and METloc001/METloc002 according to the manufacturer's instructions. LLETZ histology was the reference standard. Sensitivity and specificity of the methylation markers for cervical intraepithelial grade 2 or worse (CIN2+) and cervical intraepithelial grade 3 or worse (CIN3+). Among 89 women (median age: 67.9 years), 31 (34.8%) had CIN2+ and 16 (18.0%) had CIN3+ detected. Sensitivity for CIN2+ was similar across markers, ranging from 74.2% (95% CI: 55.4-88.1) to 77.4% (95% CI: 58.9-90.4), while specificity was lower for FAM19A4/miR124-2 (39.7%; 95% CI: 27.0-53.4) compared to ARID3C/ARL5C (65.5%; 95% CI: 51.9-77.5) and METloc001/METloc002 (82.8%; 95% CI: 70.6-91.4). Sensitivity for CIN3+ was slightly lower for FAM19A4/miR124-2 (75.0%; 95% CI: 47.6-92.7) compared to ARID3C/ARL3C (87.5%; 95% CI: 61.7-98.4) and METloc001/METloc002 (93.8%; 95% CI: 69.8-99.8). Similarly, specificity was lowest for FAM19A4/miR124-2 (35.6%; 95% CI: 24.7-47.7), higher for ARID3C/ARL5C (60.3%; 95% CI: 48.1-71.5) and highest for METloc001/METloc002 (93.8%; 95% CI: 63.9-84.7). Methylation markers, particularly METloc001/METloc002, may be useful for risk-based management of women with a TZ3 at colposcopy. ClinicalTrials.gov identifier: NCT04298957 (https://www. gov/ct2/show/NCT04298957?term=NCT04298957&draw=2&rank=1).